Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CSL Vifor
The European Medicines Agency has OKd two new H5N1 jabs, including a pandemic preparedness vaccine intended for use only if a flu pandemic is declared. Eight other products are also heading for EU-wide approval.
Developers of three new drugs, including two orphan medicines, that are nearing the final stages of their EU regulatory review cycle could be asked to explain why the European Medicines Agency should recommend approval of their products.
Four new orphan medicines were among the products recommended for pan-EU marketing approval by the European Medicines Agency this week.
The European Medicines Agency is this week due to decide whether to recommend pan-EU marketing authorization for a number of new products.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Vifor Pharma Group, Vifor Pharma Management Ltd./ Subsidiaries: Aspreva Pharmaceuticals Corporation
- Galenica Group
- Relypsa, Inc.
- Vifor Pharma
- Vifor-Fresenius Medical Care Renal Pharma Ltd.
- OM Pharma
- Sanifit Therapeutics S.A.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.